SlideShare a Scribd company logo
1 of 36
DR. REEMA KUMARI
Associate professor
Department of community medicine and public health
K.G. Medical University, Lucknow
 An acute infectious disease, usually of young children
caused by B.pertussis.
 Insidious onset with mild fever and an irritating cough
gradually becoming paroxyamal with the characteristic
“whoop”( loud crowing inspiration)
 The Chinese call it a “ Hundred Day Cough”
 Pertussis toxin and
filamentous
hemagglutinin (FHA)
allow binding of
pertussis to respiratory
epithelial cells.
 PT can then enter the
bloodstream.
 Pertussis is a disease of worldwide importance, with
an estimated 285,000 deaths in 2001, with most
occurring in Africa and SE Asia
 According to the WHO,2010 there are 1.29 lacs cases
reported globally, with 95% occurring in developing
countries, and the DPT(3) Immunization rate was
85%.
 In India yr.1987 incidence was 1.63 lacs cases, in
2011only 39,091 cases were reported (decline of
76%)
 AGENT FACTORS
 B. pertussis is very contagious, and attack rates
among susceptible groups range from 50-100%
depending on the nature of the exposure.
 B. pertusis occurs in smooth and rough phases,
capsulated and non-capsulated form, elaborates an
exotoxins and endotoxins
 B. pertusis is antigenically highly complex. It carries
3 major agglutinogens-1,2,3 and several minor ones
 Survives only for very short periods outside the
human body
Bordetella pertusis
AGE: disease of infants and pre-school children;
however, children under the age of 5 years are at the
highest risk of developing more serious symptoms.
Being in close contact with an infected person for
extended periods of time increases the risk of
becoming infected
IMMUNITY: recovery from whooping cough or
adequate immunization is followed by immunity.
Infants are susceptible to infection from birth bec.
Maternal antibody does not appear to give them
protection. no cross immunity with B. Parapertussis
 B. pertusis infects only man, source is a case of
pertusis
 Transmission is felt to occur by aerosol droplet, and
exposure to a coughing patient.
 There are no known animal reservoirs for B pertussis,
and the organism does not survive for prolonged
periods in the environment.
 No long-term carrier state had been identified, but
asymptomatic culture positive persons can be
detected during known exposures.
 The bacilli occurs abundantly in the nasopharyngeal
and bronchial secretions, which are infective
 Objects freshly contaminated by such discharges are
also infective
 Whooping cough is most infectious during catarrhal
stage.
 The infective period may be considered to extend
from a week after exposure to about 3 weeks after the
onset of paroxysmal stage
 Whole cell pertussis vaccine has been responsible for
a major reduction in disease incidence, but has caused
a shift in the peak age of disease.
Stage 1 (Catarrhal):
 Cold, runny nose and irritating cough
 Most infectious stage
Stage 2 (Paroxysmal):
 Severe series of coughs usually ending with a high-
pitched whoop
 The whoop starts 1 to 2 weeks after the cold
symptoms and lasts 1 to 2 months
 Thick, clear, sticky mucous may be coughed up at the
end of the coughing spasm
 Coughing spasms are more frequent at night
Stage 3 (Convalescent):
 Gradual disappearance of symptoms occurring over
2 to 4 weeks, however, coughing spells can last for
weeks or months
 Cough may become louder and may sound like it is
getting worse as the person is getting better
 Coughing may flare up again later in a cold or upper
respiratory illness. This does not mean that the
person has been re-infected with pertussis
 After an incubation period of 1-3 weeks, signs and
symptoms of the catarrhal phase begin
 Symptoms include rhinorrhea, lacrimation,
conjunctival injection, malaise, low grade fever, and
are indistinguishable from those of many other URI’s.
 After a few days and up to a week of these
symptoms, a dry nonproductive cough develops, and
this evolves into a characteristic paroxysmal phase.
 Patients are most contagious during the catarrhal
phase and during the first two weeks after the onset
of coughing.
 Prodromal symptoms during this phase can include
complaints of pharyngeal discomfort.
 During this phase, patients can develop a marked
leukocytosis, with WBC counts greater than 50,000,
with a relative lymphocytosis (less common in
adults).
 The cough paroxysm consists of a short series of
expiratory bursts, followed by an inspiratory gasp,
which results in the typical “whoop”.
 The paroxysmal phase usually lasts 1-6 weeks, but
can last up to 10 weeks
 Not all children with pertussis exhibit the
characteristic whoop, and it is fairly uncommon in
infants, who may have apneic episodes
Child having Loud crowing inspiration
 In adults, whooping is variable, ranging from 20-40%
in various studies. The disease is generally milder,
but the paroxysmal cough may be just as prolonged.
 Paroxysms can number more than 30 per 24 hours,
and are more frequent at night, and can be stimulated
by external stimuli, such as noises or cold air.
 Classically they may end with a vomiting episode.
They can be associated with sweating, flushing and
syncope. Patients may cough up thick yellow plugs.
 Pertussis is generally more severe in infants, but
presentation can be more atypical in infants, as well
as partially immunized children and previously
immunized adolescents and adults.
 In these groups the catarrhal phase can be shortened,
and the true whooping phase may be absent.
 The convalescent phase begins with a decrease in the
intensity of the cough and paroxysms, but can still
last for weeks.
 It is not clear if pertussis can cause long term
impairment of pulmonary function.
 Complications occurs in 5-6 percent of cases
 The chief complications of pertussis are bronchitis,
bronchopneumonia and bronchiactasis
 secondary infections-otitis media or pneumonia
(either secondary to pertussis or other organisms)
 Aspiration can occur secondary to the whooping and
associated gasping
 Patients can develop subconjunctival hemorrhages,
epistaxis, haemoptysis and punctate cerebral
haemorrhages which may cause convulsions and
coma
 CNS abnormalities can occur particularly in children
6 months and younger.
 Direct fluorescent antibody tests (DFA) are often
used as well, but they can be less sensitive and less
specific, and may lead to overdiagnosis and
overtreatment (higher false positives from cross
reaction with normal naso-pharyngeal flora).
 With new PCR technology becoming available, the
ability to diagnose Bordetella infection has been
greatly enhanced
 A clinical case is defined as a cough illness lasting at
least 2 weeks without other apparent cause
accompanied by one of the following
 Paroxysms of coughing
 Inspiratory ‘whoop’
 Posttussive vomiting
 The newer macrolides (azithromycin and
clarithromycin) have good in vitro acitivity against B
pertussis, and
 Clarithromycin (500 mg bid) used for 10 – 14 days
 Azithromycin (500 mg/d) used for 5 – 7 days have
been used with good results.
 Steroids may reduce the number and severity of
cough paroxysms, but are generally only
recommended for infants with serious disease.
 Antibiotics can be used for 2 purposes in the control
and prevention of pertussis :
1. Treatment to modify clinical symptoms of pertussis
by administering to symptomatic patients
 Prevention of secondary spread of pertussis by
administering to:
 Symptomatic patients (treatment) and interrupting
infectiousness and transmission by eliminating the
organism from the respiratory system.
 Asymptomatic contacts (prophylaxis) and
interrupting transmission by eliminating any
organisms that may have been contracted
 Other methods of preventing the spread of Pertussis
include:
 Washing hands with soap and warm water.
 Teaching children to cover mouth and nose if
coughing or sneezing and to wash hands after doing
so.
 Not sharing eating utensils and drinking glasses.
 Minimizing the amount of contact you have with
someone you know is infected or if you are infected,
minimizing the amount of time you are around
others.
THANK YOU

More Related Content

Similar to whooping cough lecture...............ppt

Whooping cough | pertussis ( medical information ) - a detailed study
Whooping cough | pertussis ( medical information ) - a detailed studyWhooping cough | pertussis ( medical information ) - a detailed study
Whooping cough | pertussis ( medical information ) - a detailed studymartinshaji
 
Pertussis (whooping cough)
Pertussis (whooping cough)Pertussis (whooping cough)
Pertussis (whooping cough)Razwan2
 
C A S E P R E S E N T A T I O N Paeds3
C A S E  P R E S E N T A T I O N Paeds3C A S E  P R E S E N T A T I O N Paeds3
C A S E P R E S E N T A T I O N Paeds3Raymond Arhin
 
Pertussis/Whooping cough
Pertussis/Whooping coughPertussis/Whooping cough
Pertussis/Whooping coughChiara Salalima
 
Pertussis (whooping cough)
Pertussis (whooping cough)Pertussis (whooping cough)
Pertussis (whooping cough)D.A.B.M
 
Nursing management Lower respiratort problems.pptx
Nursing management Lower respiratort problems.pptxNursing management Lower respiratort problems.pptx
Nursing management Lower respiratort problems.pptxIbrahimkargbo10
 
Community acquired pneumonia [cap] in children
Community acquired pneumonia [cap] in childrenCommunity acquired pneumonia [cap] in children
Community acquired pneumonia [cap] in childrenHardik Shah
 
Lower Respiratory Tract Infections Presentation
Lower Respiratory Tract Infections PresentationLower Respiratory Tract Infections Presentation
Lower Respiratory Tract Infections PresentationYara Mohamed
 
New microsoft power point presentation
New microsoft power point presentationNew microsoft power point presentation
New microsoft power point presentationMahtab Alam
 
Acute respiratory infection (ARI)
Acute respiratory infection (ARI)Acute respiratory infection (ARI)
Acute respiratory infection (ARI)Mohammed Musa
 

Similar to whooping cough lecture...............ppt (20)

whooping cough.ppt
whooping cough.pptwhooping cough.ppt
whooping cough.ppt
 
Pertusis ( Whooping Cough)
Pertusis ( Whooping Cough)Pertusis ( Whooping Cough)
Pertusis ( Whooping Cough)
 
Whooping cough | pertussis ( medical information ) - a detailed study
Whooping cough | pertussis ( medical information ) - a detailed studyWhooping cough | pertussis ( medical information ) - a detailed study
Whooping cough | pertussis ( medical information ) - a detailed study
 
Pertussis
PertussisPertussis
Pertussis
 
Pertussis (whooping cough)
Pertussis (whooping cough)Pertussis (whooping cough)
Pertussis (whooping cough)
 
C A S E P R E S E N T A T I O N Paeds3
C A S E  P R E S E N T A T I O N Paeds3C A S E  P R E S E N T A T I O N Paeds3
C A S E P R E S E N T A T I O N Paeds3
 
Pertussis/Whooping cough
Pertussis/Whooping coughPertussis/Whooping cough
Pertussis/Whooping cough
 
Pertussis (whooping cough)
Pertussis (whooping cough)Pertussis (whooping cough)
Pertussis (whooping cough)
 
Nursing management Lower respiratort problems.pptx
Nursing management Lower respiratort problems.pptxNursing management Lower respiratort problems.pptx
Nursing management Lower respiratort problems.pptx
 
UNDER 5 29 SEP.pptx
UNDER 5 29 SEP.pptxUNDER 5 29 SEP.pptx
UNDER 5 29 SEP.pptx
 
Bordetella pertussis depa
Bordetella pertussis depaBordetella pertussis depa
Bordetella pertussis depa
 
Community acquired pneumonia [cap] in children
Community acquired pneumonia [cap] in childrenCommunity acquired pneumonia [cap] in children
Community acquired pneumonia [cap] in children
 
15 Pertusis.pptx
15 Pertusis.pptx15 Pertusis.pptx
15 Pertusis.pptx
 
Whooping cough
Whooping coughWhooping cough
Whooping cough
 
Pertusis
PertusisPertusis
Pertusis
 
Pertusis and Varicella
Pertusis and VaricellaPertusis and Varicella
Pertusis and Varicella
 
Lower Respiratory Tract Infections Presentation
Lower Respiratory Tract Infections PresentationLower Respiratory Tract Infections Presentation
Lower Respiratory Tract Infections Presentation
 
New microsoft power point presentation
New microsoft power point presentationNew microsoft power point presentation
New microsoft power point presentation
 
pneumonia.pptx
pneumonia.pptxpneumonia.pptx
pneumonia.pptx
 
Acute respiratory infection (ARI)
Acute respiratory infection (ARI)Acute respiratory infection (ARI)
Acute respiratory infection (ARI)
 

More from DebdattaMandal5

renalfunctiontests-130723211756-phpapp01.pptx
renalfunctiontests-130723211756-phpapp01.pptxrenalfunctiontests-130723211756-phpapp01.pptx
renalfunctiontests-130723211756-phpapp01.pptxDebdattaMandal5
 
Imaging of the Renal System..........ppt
Imaging of the Renal System..........pptImaging of the Renal System..........ppt
Imaging of the Renal System..........pptDebdattaMandal5
 
DOC-20230308-WA0008.................pptx
DOC-20230308-WA0008.................pptxDOC-20230308-WA0008.................pptx
DOC-20230308-WA0008.................pptxDebdattaMandal5
 
labdiagnosisinrenaldiseases-copy-180611071550.pptx
labdiagnosisinrenaldiseases-copy-180611071550.pptxlabdiagnosisinrenaldiseases-copy-180611071550.pptx
labdiagnosisinrenaldiseases-copy-180611071550.pptxDebdattaMandal5
 
kidneydisorders-151105065618-lva1-app6892.ppt
kidneydisorders-151105065618-lva1-app6892.pptkidneydisorders-151105065618-lva1-app6892.ppt
kidneydisorders-151105065618-lva1-app6892.pptDebdattaMandal5
 
introductionadministrationmanagement-170719152235.pptx
introductionadministrationmanagement-170719152235.pptxintroductionadministrationmanagement-170719152235.pptx
introductionadministrationmanagement-170719152235.pptxDebdattaMandal5
 
multiple pregnancy....................pptx
multiple pregnancy....................pptxmultiple pregnancy....................pptx
multiple pregnancy....................pptxDebdattaMandal5
 
hypertensivedisordersofpregnancy-180930162838.pptx
hypertensivedisordersofpregnancy-180930162838.pptxhypertensivedisordersofpregnancy-180930162838.pptx
hypertensivedisordersofpregnancy-180930162838.pptxDebdattaMandal5
 
epidemiology-16062704353..........4.pptx
epidemiology-16062704353..........4.pptxepidemiology-16062704353..........4.pptx
epidemiology-16062704353..........4.pptxDebdattaMandal5
 
epidemiologypreventionandcontrolofplague-160627043327.pptx
epidemiologypreventionandcontrolofplague-160627043327.pptxepidemiologypreventionandcontrolofplague-160627043327.pptx
epidemiologypreventionandcontrolofplague-160627043327.pptxDebdattaMandal5
 
typhoidfeverppt-1812021.......24043.pptx
typhoidfeverppt-1812021.......24043.pptxtyphoidfeverppt-1812021.......24043.pptx
typhoidfeverppt-1812021.......24043.pptxDebdattaMandal5
 
tetanus-1205111525..28-phpapp02 (2).pptx
tetanus-1205111525..28-phpapp02 (2).pptxtetanus-1205111525..28-phpapp02 (2).pptx
tetanus-1205111525..28-phpapp02 (2).pptxDebdattaMandal5
 
poliomyelitis-1908102.........00943.pptx
poliomyelitis-1908102.........00943.pptxpoliomyelitis-1908102.........00943.pptx
poliomyelitis-1908102.........00943.pptxDebdattaMandal5
 
covidvaccines-210821171459...........pptx
covidvaccines-210821171459...........pptxcovidvaccines-210821171459...........pptx
covidvaccines-210821171459...........pptxDebdattaMandal5
 
covid-200424062237..................pptx
covid-200424062237..................pptxcovid-200424062237..................pptx
covid-200424062237..................pptxDebdattaMandal5
 
tetanus-120511152528-phpapp0. .pptx
tetanus-120511152528-phpapp0.        .pptxtetanus-120511152528-phpapp0.        .pptx
tetanus-120511152528-phpapp0. .pptxDebdattaMandal5
 
meningitis-170131181426888888888888.pptx
meningitis-170131181426888888888888.pptxmeningitis-170131181426888888888888.pptx
meningitis-170131181426888888888888.pptxDebdattaMandal5
 
gasgangrene-200701120813............pptx
gasgangrene-200701120813............pptxgasgangrene-200701120813............pptx
gasgangrene-200701120813............pptxDebdattaMandal5
 
dengueepidemiology-200501161658.....pptx
dengueepidemiology-200501161658.....pptxdengueepidemiology-200501161658.....pptx
dengueepidemiology-200501161658.....pptxDebdattaMandal5
 
284.26_lecture3kkkkkkkkkkkkkkkkkkkkk.ppt
284.26_lecture3kkkkkkkkkkkkkkkkkkkkk.ppt284.26_lecture3kkkkkkkkkkkkkkkkkkkkk.ppt
284.26_lecture3kkkkkkkkkkkkkkkkkkkkk.pptDebdattaMandal5
 

More from DebdattaMandal5 (20)

renalfunctiontests-130723211756-phpapp01.pptx
renalfunctiontests-130723211756-phpapp01.pptxrenalfunctiontests-130723211756-phpapp01.pptx
renalfunctiontests-130723211756-phpapp01.pptx
 
Imaging of the Renal System..........ppt
Imaging of the Renal System..........pptImaging of the Renal System..........ppt
Imaging of the Renal System..........ppt
 
DOC-20230308-WA0008.................pptx
DOC-20230308-WA0008.................pptxDOC-20230308-WA0008.................pptx
DOC-20230308-WA0008.................pptx
 
labdiagnosisinrenaldiseases-copy-180611071550.pptx
labdiagnosisinrenaldiseases-copy-180611071550.pptxlabdiagnosisinrenaldiseases-copy-180611071550.pptx
labdiagnosisinrenaldiseases-copy-180611071550.pptx
 
kidneydisorders-151105065618-lva1-app6892.ppt
kidneydisorders-151105065618-lva1-app6892.pptkidneydisorders-151105065618-lva1-app6892.ppt
kidneydisorders-151105065618-lva1-app6892.ppt
 
introductionadministrationmanagement-170719152235.pptx
introductionadministrationmanagement-170719152235.pptxintroductionadministrationmanagement-170719152235.pptx
introductionadministrationmanagement-170719152235.pptx
 
multiple pregnancy....................pptx
multiple pregnancy....................pptxmultiple pregnancy....................pptx
multiple pregnancy....................pptx
 
hypertensivedisordersofpregnancy-180930162838.pptx
hypertensivedisordersofpregnancy-180930162838.pptxhypertensivedisordersofpregnancy-180930162838.pptx
hypertensivedisordersofpregnancy-180930162838.pptx
 
epidemiology-16062704353..........4.pptx
epidemiology-16062704353..........4.pptxepidemiology-16062704353..........4.pptx
epidemiology-16062704353..........4.pptx
 
epidemiologypreventionandcontrolofplague-160627043327.pptx
epidemiologypreventionandcontrolofplague-160627043327.pptxepidemiologypreventionandcontrolofplague-160627043327.pptx
epidemiologypreventionandcontrolofplague-160627043327.pptx
 
typhoidfeverppt-1812021.......24043.pptx
typhoidfeverppt-1812021.......24043.pptxtyphoidfeverppt-1812021.......24043.pptx
typhoidfeverppt-1812021.......24043.pptx
 
tetanus-1205111525..28-phpapp02 (2).pptx
tetanus-1205111525..28-phpapp02 (2).pptxtetanus-1205111525..28-phpapp02 (2).pptx
tetanus-1205111525..28-phpapp02 (2).pptx
 
poliomyelitis-1908102.........00943.pptx
poliomyelitis-1908102.........00943.pptxpoliomyelitis-1908102.........00943.pptx
poliomyelitis-1908102.........00943.pptx
 
covidvaccines-210821171459...........pptx
covidvaccines-210821171459...........pptxcovidvaccines-210821171459...........pptx
covidvaccines-210821171459...........pptx
 
covid-200424062237..................pptx
covid-200424062237..................pptxcovid-200424062237..................pptx
covid-200424062237..................pptx
 
tetanus-120511152528-phpapp0. .pptx
tetanus-120511152528-phpapp0.        .pptxtetanus-120511152528-phpapp0.        .pptx
tetanus-120511152528-phpapp0. .pptx
 
meningitis-170131181426888888888888.pptx
meningitis-170131181426888888888888.pptxmeningitis-170131181426888888888888.pptx
meningitis-170131181426888888888888.pptx
 
gasgangrene-200701120813............pptx
gasgangrene-200701120813............pptxgasgangrene-200701120813............pptx
gasgangrene-200701120813............pptx
 
dengueepidemiology-200501161658.....pptx
dengueepidemiology-200501161658.....pptxdengueepidemiology-200501161658.....pptx
dengueepidemiology-200501161658.....pptx
 
284.26_lecture3kkkkkkkkkkkkkkkkkkkkk.ppt
284.26_lecture3kkkkkkkkkkkkkkkkkkkkk.ppt284.26_lecture3kkkkkkkkkkkkkkkkkkkkk.ppt
284.26_lecture3kkkkkkkkkkkkkkkkkkkkk.ppt
 

Recently uploaded

Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...Jisc
 
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTiammrhaywood
 
Roles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceRoles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceSamikshaHamane
 
Solving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxSolving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxOH TEIK BIN
 
Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)Mark Reed
 
Crayon Activity Handout For the Crayon A
Crayon Activity Handout For the Crayon ACrayon Activity Handout For the Crayon A
Crayon Activity Handout For the Crayon AUnboundStockton
 
ENGLISH6-Q4-W3.pptxqurter our high choom
ENGLISH6-Q4-W3.pptxqurter our high choomENGLISH6-Q4-W3.pptxqurter our high choom
ENGLISH6-Q4-W3.pptxqurter our high choomnelietumpap1
 
ROOT CAUSE ANALYSIS PowerPoint Presentation
ROOT CAUSE ANALYSIS PowerPoint PresentationROOT CAUSE ANALYSIS PowerPoint Presentation
ROOT CAUSE ANALYSIS PowerPoint PresentationAadityaSharma884161
 
What is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERPWhat is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERPCeline George
 
Grade 9 Q4-MELC1-Active and Passive Voice.pptx
Grade 9 Q4-MELC1-Active and Passive Voice.pptxGrade 9 Q4-MELC1-Active and Passive Voice.pptx
Grade 9 Q4-MELC1-Active and Passive Voice.pptxChelloAnnAsuncion2
 
AmericanHighSchoolsprezentacijaoskolama.
AmericanHighSchoolsprezentacijaoskolama.AmericanHighSchoolsprezentacijaoskolama.
AmericanHighSchoolsprezentacijaoskolama.arsicmarija21
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxpboyjonauth
 
Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Celine George
 
How to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPHow to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPCeline George
 
Alper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentAlper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentInMediaRes1
 
Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Celine George
 
Romantic Opera MUSIC FOR GRADE NINE pptx
Romantic Opera MUSIC FOR GRADE NINE pptxRomantic Opera MUSIC FOR GRADE NINE pptx
Romantic Opera MUSIC FOR GRADE NINE pptxsqpmdrvczh
 
ACC 2024 Chronicles. Cardiology. Exam.pdf
ACC 2024 Chronicles. Cardiology. Exam.pdfACC 2024 Chronicles. Cardiology. Exam.pdf
ACC 2024 Chronicles. Cardiology. Exam.pdfSpandanaRallapalli
 

Recently uploaded (20)

Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...
 
Model Call Girl in Bikash Puri Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Bikash Puri  Delhi reach out to us at 🔝9953056974🔝Model Call Girl in Bikash Puri  Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Bikash Puri Delhi reach out to us at 🔝9953056974🔝
 
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
 
Roles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceRoles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in Pharmacovigilance
 
Solving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxSolving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptx
 
Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)
 
Crayon Activity Handout For the Crayon A
Crayon Activity Handout For the Crayon ACrayon Activity Handout For the Crayon A
Crayon Activity Handout For the Crayon A
 
ENGLISH6-Q4-W3.pptxqurter our high choom
ENGLISH6-Q4-W3.pptxqurter our high choomENGLISH6-Q4-W3.pptxqurter our high choom
ENGLISH6-Q4-W3.pptxqurter our high choom
 
ROOT CAUSE ANALYSIS PowerPoint Presentation
ROOT CAUSE ANALYSIS PowerPoint PresentationROOT CAUSE ANALYSIS PowerPoint Presentation
ROOT CAUSE ANALYSIS PowerPoint Presentation
 
What is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERPWhat is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERP
 
Grade 9 Q4-MELC1-Active and Passive Voice.pptx
Grade 9 Q4-MELC1-Active and Passive Voice.pptxGrade 9 Q4-MELC1-Active and Passive Voice.pptx
Grade 9 Q4-MELC1-Active and Passive Voice.pptx
 
AmericanHighSchoolsprezentacijaoskolama.
AmericanHighSchoolsprezentacijaoskolama.AmericanHighSchoolsprezentacijaoskolama.
AmericanHighSchoolsprezentacijaoskolama.
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptx
 
Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17
 
How to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPHow to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERP
 
Alper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentAlper Gobel In Media Res Media Component
Alper Gobel In Media Res Media Component
 
Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17
 
OS-operating systems- ch04 (Threads) ...
OS-operating systems- ch04 (Threads) ...OS-operating systems- ch04 (Threads) ...
OS-operating systems- ch04 (Threads) ...
 
Romantic Opera MUSIC FOR GRADE NINE pptx
Romantic Opera MUSIC FOR GRADE NINE pptxRomantic Opera MUSIC FOR GRADE NINE pptx
Romantic Opera MUSIC FOR GRADE NINE pptx
 
ACC 2024 Chronicles. Cardiology. Exam.pdf
ACC 2024 Chronicles. Cardiology. Exam.pdfACC 2024 Chronicles. Cardiology. Exam.pdf
ACC 2024 Chronicles. Cardiology. Exam.pdf
 

whooping cough lecture...............ppt

  • 1. DR. REEMA KUMARI Associate professor Department of community medicine and public health K.G. Medical University, Lucknow
  • 2.  An acute infectious disease, usually of young children caused by B.pertussis.  Insidious onset with mild fever and an irritating cough gradually becoming paroxyamal with the characteristic “whoop”( loud crowing inspiration)  The Chinese call it a “ Hundred Day Cough”
  • 3.
  • 4.  Pertussis toxin and filamentous hemagglutinin (FHA) allow binding of pertussis to respiratory epithelial cells.  PT can then enter the bloodstream.
  • 5.  Pertussis is a disease of worldwide importance, with an estimated 285,000 deaths in 2001, with most occurring in Africa and SE Asia  According to the WHO,2010 there are 1.29 lacs cases reported globally, with 95% occurring in developing countries, and the DPT(3) Immunization rate was 85%.  In India yr.1987 incidence was 1.63 lacs cases, in 2011only 39,091 cases were reported (decline of 76%)
  • 6.
  • 7.  AGENT FACTORS  B. pertussis is very contagious, and attack rates among susceptible groups range from 50-100% depending on the nature of the exposure.  B. pertusis occurs in smooth and rough phases, capsulated and non-capsulated form, elaborates an exotoxins and endotoxins  B. pertusis is antigenically highly complex. It carries 3 major agglutinogens-1,2,3 and several minor ones  Survives only for very short periods outside the human body
  • 9. AGE: disease of infants and pre-school children; however, children under the age of 5 years are at the highest risk of developing more serious symptoms. Being in close contact with an infected person for extended periods of time increases the risk of becoming infected IMMUNITY: recovery from whooping cough or adequate immunization is followed by immunity. Infants are susceptible to infection from birth bec. Maternal antibody does not appear to give them protection. no cross immunity with B. Parapertussis
  • 10.  B. pertusis infects only man, source is a case of pertusis  Transmission is felt to occur by aerosol droplet, and exposure to a coughing patient.  There are no known animal reservoirs for B pertussis, and the organism does not survive for prolonged periods in the environment.  No long-term carrier state had been identified, but asymptomatic culture positive persons can be detected during known exposures.
  • 11.
  • 12.  The bacilli occurs abundantly in the nasopharyngeal and bronchial secretions, which are infective  Objects freshly contaminated by such discharges are also infective
  • 13.  Whooping cough is most infectious during catarrhal stage.  The infective period may be considered to extend from a week after exposure to about 3 weeks after the onset of paroxysmal stage
  • 14.  Whole cell pertussis vaccine has been responsible for a major reduction in disease incidence, but has caused a shift in the peak age of disease.
  • 15. Stage 1 (Catarrhal):  Cold, runny nose and irritating cough  Most infectious stage Stage 2 (Paroxysmal):  Severe series of coughs usually ending with a high- pitched whoop  The whoop starts 1 to 2 weeks after the cold symptoms and lasts 1 to 2 months  Thick, clear, sticky mucous may be coughed up at the end of the coughing spasm  Coughing spasms are more frequent at night
  • 16. Stage 3 (Convalescent):  Gradual disappearance of symptoms occurring over 2 to 4 weeks, however, coughing spells can last for weeks or months  Cough may become louder and may sound like it is getting worse as the person is getting better  Coughing may flare up again later in a cold or upper respiratory illness. This does not mean that the person has been re-infected with pertussis
  • 17.  After an incubation period of 1-3 weeks, signs and symptoms of the catarrhal phase begin  Symptoms include rhinorrhea, lacrimation, conjunctival injection, malaise, low grade fever, and are indistinguishable from those of many other URI’s.  After a few days and up to a week of these symptoms, a dry nonproductive cough develops, and this evolves into a characteristic paroxysmal phase.
  • 18.  Patients are most contagious during the catarrhal phase and during the first two weeks after the onset of coughing.  Prodromal symptoms during this phase can include complaints of pharyngeal discomfort.  During this phase, patients can develop a marked leukocytosis, with WBC counts greater than 50,000, with a relative lymphocytosis (less common in adults).
  • 19.  The cough paroxysm consists of a short series of expiratory bursts, followed by an inspiratory gasp, which results in the typical “whoop”.  The paroxysmal phase usually lasts 1-6 weeks, but can last up to 10 weeks  Not all children with pertussis exhibit the characteristic whoop, and it is fairly uncommon in infants, who may have apneic episodes
  • 20. Child having Loud crowing inspiration
  • 21.  In adults, whooping is variable, ranging from 20-40% in various studies. The disease is generally milder, but the paroxysmal cough may be just as prolonged.  Paroxysms can number more than 30 per 24 hours, and are more frequent at night, and can be stimulated by external stimuli, such as noises or cold air.
  • 22.  Classically they may end with a vomiting episode. They can be associated with sweating, flushing and syncope. Patients may cough up thick yellow plugs.  Pertussis is generally more severe in infants, but presentation can be more atypical in infants, as well as partially immunized children and previously immunized adolescents and adults.  In these groups the catarrhal phase can be shortened, and the true whooping phase may be absent.
  • 23.  The convalescent phase begins with a decrease in the intensity of the cough and paroxysms, but can still last for weeks.  It is not clear if pertussis can cause long term impairment of pulmonary function.
  • 24.
  • 25.  Complications occurs in 5-6 percent of cases  The chief complications of pertussis are bronchitis, bronchopneumonia and bronchiactasis  secondary infections-otitis media or pneumonia (either secondary to pertussis or other organisms)  Aspiration can occur secondary to the whooping and associated gasping
  • 26.  Patients can develop subconjunctival hemorrhages, epistaxis, haemoptysis and punctate cerebral haemorrhages which may cause convulsions and coma  CNS abnormalities can occur particularly in children 6 months and younger.
  • 27.  Direct fluorescent antibody tests (DFA) are often used as well, but they can be less sensitive and less specific, and may lead to overdiagnosis and overtreatment (higher false positives from cross reaction with normal naso-pharyngeal flora).  With new PCR technology becoming available, the ability to diagnose Bordetella infection has been greatly enhanced
  • 28.  A clinical case is defined as a cough illness lasting at least 2 weeks without other apparent cause accompanied by one of the following  Paroxysms of coughing  Inspiratory ‘whoop’  Posttussive vomiting
  • 29.  The newer macrolides (azithromycin and clarithromycin) have good in vitro acitivity against B pertussis, and  Clarithromycin (500 mg bid) used for 10 – 14 days  Azithromycin (500 mg/d) used for 5 – 7 days have been used with good results.
  • 30.  Steroids may reduce the number and severity of cough paroxysms, but are generally only recommended for infants with serious disease.
  • 31.
  • 32.  Antibiotics can be used for 2 purposes in the control and prevention of pertussis : 1. Treatment to modify clinical symptoms of pertussis by administering to symptomatic patients
  • 33.  Prevention of secondary spread of pertussis by administering to:  Symptomatic patients (treatment) and interrupting infectiousness and transmission by eliminating the organism from the respiratory system.  Asymptomatic contacts (prophylaxis) and interrupting transmission by eliminating any organisms that may have been contracted
  • 34.
  • 35.  Other methods of preventing the spread of Pertussis include:  Washing hands with soap and warm water.  Teaching children to cover mouth and nose if coughing or sneezing and to wash hands after doing so.  Not sharing eating utensils and drinking glasses.  Minimizing the amount of contact you have with someone you know is infected or if you are infected, minimizing the amount of time you are around others.